KRAS and cancer: While anti-EGFR-targeted monoclonal antibodies, such as panitumumab and cetuximab, have found reasonable ground against cancers with an abnormal EGFR activation upstream of a wild-type KRAS (wtKRAS), cancer patients with a mutant KRAS showed no therapeutic benefit from such therapies, rendering mutant KRAS a predictive biomarker for negative therapeutic response in anti-EGFR therapy [3,4,5,6].